2002-2010年業績

2013

1
Wada H., Kageyama S., Muro K., Niwa Y., Ueda S., Miyata H., Takiguchi S., Sugino SH., Miyahara Y., Ikeda H., Imai N., Sato E., Yamada T., Osako M., Ohnishi M., Harada N., Hishida T., Doki Y., Shiku H. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med 11(1): 246, 2013

2
Nagano H., Kobayashi S., Marubashi S., Wada H., Eguchi H., Tanemura M., Tomimaru Y., Umeshita K., Doki Y., Mori M. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med 5(1): 3-10, 2013

3
Nagano H., Tomimaru Y., Eguchi H., Hama N., Wada H., Kawamoto K., Kobayashi S., Mori M., Doki Y. MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol 43(4): 1066-1072, 2013

4
Yamamoto H., Oshiro R., Ohtsuka M., Uemura M., Haraguchi N., Nishimura J., Takemasa I., Mizushima T., Doki Y., Mori M. Distinct expression of C4.4A in colorectal cancer detected by different antibodies. Int J Oncol 42(1): 197-201, 2013

5
Yamamoto H., Tei M., Uemura M., Takemasa I., Uemura Y., Murata K., Fukunaga M., Ohue M., Ohnishi T., Ikeda K., Kato T., Okamura S., Ikenaga M., Haraguchi N., Nishimura J., Mizushima T., Mimori K., Doki Y., Mori M. Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer. Int J Oncol 42(2): 549-555, 2013

6
Yamamoto H., Yamamoto H., Chowdhury EH., Wu X., Hirose H., Haque A., Doki Y., Mori M., Akaike T. Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: effect on growth retardation of established colon tumor. PLoS One 8(4): 60428, 2013

7
Takiguchi S., Hiura Y., Takahashi T., Kurokawa Y., Yamasaki M., Nakajima K., Miyata H., Mori M., Hosoda H., Kangawa K., Doki Y. Effect of rikkunshito, a Japanese herbal medicine, on gastrointestinal symptoms and ghrelin levels in gastric cancer patients after gastrectomy. Gastric Cancer 16(2): 167-174, 2013

8
Takiguchi S., Fujiwara Y, Yamasaki M, Miyata H, Nakajima K, Sekimoto M, Mori M, Doki Y. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg 37(10): 2379-2386, 2013

9
Takiguchi S., Hiura Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Mori M, Doki Y. Preservation of the Celiac Branch of the Vagus Nerve during Laparoscopy-assisted Distal Gastrectomy: Impact on Postprandial Changes in Ghrelin Secretion. World J Surg 37(9): 2172-2179, 2013

10
Eguchi H., Nagano H., Tanemura M., Takeda Y., Marubashi S., Kobayashi S., Kawamoto K., Wada H., Hama N., Akita H., Mori M., Doki Y. Preoperative Chemoradiotherapy, Surgery and Adjuvant Therapy for Resectable Pancreatic Cancer. Hepatogastroenterology 60(126): 904-911, 2013

11
Miyata H., Yamasaki M., Takahashi T., Kurokawa Y., Nakajima K., Takiguchi S., Mori M., Doki Y. Larynx-preserving limited resection and free jejunal graft for carcinoma of the cervical esophagus. World J Surg 37(3): 551-557, 2013

12
Miyata H., Yamasaki M., Takahashi T., Murakami K., Kurokawa Y., Nakajima K., Takiguchi S., Mori M., Doki Y. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer. Br J Surg 100(11): 1490-1497, 2013

13
Mizushima T., Arakawa S., Sanada Y., Yoshino I., Miyazaki D., Urushima H., Tsujimoto Y., Ito T., Shimizu S. Inhibition of Epithelial Cell Death by Bcl-2 Improved Chronic Colitis in IL-10 KO Mice. Am J Pathol 183(6): 1936-1944, 2013

14
Mizushima T., Tamagawa H., Mishima H., Ikeda K., Fujita S., Akamatsu H., Ikenaga M., Onishi T., Fukunaga M., Fukuzaki T., Hasegawa J., Takemasa I., Ikeda M., Yamamoto H., Sekimoto M., Nezu R., Doki Y., Mori M. The effects of chemotherapy on primary small bowel cancer: A retrospective multicenter observational study in Japan. Mol Clin Oncol 1(5): 820-824, 2013

15
Mizushima T., Ide Y., Murata K., Ohashi I., Yasumasa K., Fukunaga M., Takemoto H., Tamagawa H., Hasegawa J., Hata T., Takemasa I., Ikeda M., Yamamoto H., Sekimoto M., Nezu R., Doki Y., Mori M. A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer. Oncology 85(6):317-322, 2013

16
Nakajima K., Takahashi T., Souma Y., Miyazaki Y., Mori M., Doki Y. A novel percutaneous insufflating guidewire system for transgastric natural orifice translumenal endoscopic surgery (NOTES) (with video). Surg Endosc 27(3): 1016-1020, 2013

17
Nakajima K., Souma Y., Takahashi T., Yamasaki M., Miyazaki Y., Mori M., Doki Y. Anatomical measurements to optimize instrumentation for transvaginal surgery. Surg Endosc 27(6): 2052-2057, 2013

18
Nakajima K., Takahashi T., Takiguchi S., Miyata H., Yamasaki M., Kurokawa Y., Mori M., Doki Y. Successful laparoscopic Nissen fundoplication in a patient with mixed connective tissue disease with a short esophagus: report of a case. Surg Today 43(11): 1305-1309, 2013

19
Marubashi S., Wada H., Kawamoto K., Kobayashi S., Eguchi H., Doki Y., Mori M., Nagano H. Laparoscopy-assisted hybrid left-side donor hepatectomy. World J Surg 37(9): 2202-2210, 2013

20
Hata T., Fukunaga M., Murata K., Uemura Y., Fukuzaki T., Ota H., Ohue M., Ohnishi T., Tanaka N., Takemasa I., Mizushima T., Ikeda M., Yamamoto H., Sekimoto M., Nezu R., Doki Y., Mori M. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. Cancer Chemother Pharmacol 71(6): 1657-1663, 2013

21
Hata T., Kono T., Morita S., Munemoto Y., Matsui T., Kojima H., Takemoto H., Fukunaga M., Nagata N., Shimada M., Sakamoto J., Mishima H. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72(6): 1283-1290, 2013

22
Kawamoto K., Konno M., Nagano H., Nishikawa S., Tomimaru Y., Akita H., Hama N., Wada H., Kobayashi S., Eguchi H., Tanemura M., Ito T., Doki Y., Mori M., Ishii H. CD90- (Thy-1-) high selection enhances reprogramming capacity of murine adipose-derived mesenchymal stem cells. Dis Markers 35(5): 573-579, 2013

23
Kurokawa Y., Sasako M., Doki Y. Treatment approaches to esophagogastric junction tumors. Digest Surg 30(2): 169-173, 2013

24
Kurokawa Y., Shibata T., Ando N., Seki S., Mukaida H., Fukuda H. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol 20(9): 3009-3014, 2013

25
Takahashi T., Serada S., Ako M., Fujimoto M., Miyazaki Y., Nakatsuka R., Ikezoe T., Yokoyama A., Taguchi T., Shimada K., Kurokawa Y., Yamasaki M., Miyata H., Nakajima K., Takiguchi S., Mori M., Doki Y., Naka T., Nishida T. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer 133(11): 2737-2743, 2013

26
Nishimura J., Nakajima K., Souma Y., Takahashi T., Ikeguchi N., Takenaka R., Shinohara N., Nishida T., Doki Y., Mori M. The possibility of using fibrin-based collagen as an antibiotic delivery system. Surg Today 43(2): 185-190, 2013

27
Haraguchi N., Ishii H., Mimori K., Ohta K., Uemura M., Nishimura J., Hata T., Takemasa I., Mizushima T., Yamamoto H., Doki Y., Mori M. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Int J Oncol 43(2): 425-430, 2013

28
Miyazaki Y., Takiguchi S., Seki Y., Kasama K., Takahashi T., Kurokawa Y., Yamasaki M., Miyata H., Nakajima K., Mori M., Doki Y. Clinical significance of ghrelin expression in the gastric mucosa of morbidly obese patients. World J Surg 37(12): 2883-2990, 2013

29
Miyazaki Y., Nakajima K., Kurokawa Y., Takahashi T., Takiguchi S., Miyata H., Yamasaki M., Hirota S., Nishida T., Mori M., Doki Y. Clinical significance of surgery for gastric submucosal tumours with size enlargement during watchful waiting period. Eur J Cancer 49(12): 2681-2688, 2013

30
Tomimaru Y., Xu CQ., Nambotin SB., Yan T., Wands JR., Kim M. Loss of exon 4 in a human T-cell factor-4 isoform promotes hepatic tumourigenicity. Liver Int 33(10): 1536-1548,2013

31
Tomimaru Y., Eguchi H., Wada H., Hama N., Kawamoto K., Kobayashi S., Umeshita K., Doki Y., Mori M., Nagano H. Predicting the necessity of autologous blood collection and storage before surgery for hepatocellular carcinoma. J Surg Oncol 108(7): 486-491, 2013

32
Tomimaru Y., Koga H., Shin TH., Xu CQ., Wands JR., Kim M. The SxxSS motif of T-cell factor-4 isoforms modulates Wnt/β-catenin signal activation in hepatocellular carcinoma cells. Cancer Lett 336(2):359-369, 2013

33
Tomimaru Y., Koga H., Yano H., de la Monte S., Wands JR., Kim M. Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int 33(7): 1100-1112, 2013

34
Tomokuni A., Eguchi H., Hoshino H., Dewi DL., Nishikawa S., Kano Y., Miyoshi N., Tojo A., Kobayashi S., Gotoh N., Hinohara K., Fusaki N., Saito T., Suemizu H., Wada H., Kobayashi S., Marubashi S., Tanemura M., Doki Y., Mori M., Ishii H., Nagano H. Effect of in vivo administration of reprogramming factors in the mouse liver. Oncol Lett 6(2): 323-328, 2013

35
Fujiwara S., Nakajima K., Nishida T., Takahashi T., Kurokawa Y., Yamasaki M., Miyata H., Takiguchi S., Mori M., Doki Y. Gastric schwannomas revisited: has precise preoperative diagnosis become feasible? Gastric Cancer 16(3): 318-323,2013

36
Fujiwara S., Wada H., Kawada J., Kawabata R., Takahashi T., Fujita J., Hirao T., Shibata K., Makari Y., Iijima S., Nishikawa H., Jungbluth AA., Nakamura Y., Kurokawa Y., Yamasaki M., Miyata H., Nakajima K., Takiguchi S., Nakayama E., Mori M., Doki Y. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer 108(5): 1119-1125, 2013

37
Ohta K., Haraguchi N., Kano Y., Kagawa Y., Konno M., Nishikawa S., Hamabe A., Hasegawa S., Ogawa H., Fukusumi T., Uemura M., Nishimura J., Hata T., Takemasa I., Mizushima T., Noguchi Y., Ozaki M., Kudo T., Sakai D., Satoh T., Fukami M., Ishii M., Yamamoto H., Doki Y., Mori M., Ishii H. Depletion of JARID1B induces cellular senescence in human colorectal cancer. Int J Oncol 42(4):1212-1218, 2013

38
Okada K., Fujiwara Y., Takahashi T., Nakamura Y., Takiguchi S., Nakajima K., Miyata H., Yamasaki M., Kurokawa Y., Mori M., Doki Y. Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer. Ann Surg Oncol 20(3): 1035-1043, 2013

39
Suzuki Y., Haraguchi N., Takahashi H., Uemura M., Nishimura J., Hata T., Takemasa I., Mizushima T., Ishii H., Doki Y., Mori M., Yamamoto H. SSEA-3 as a novel amplifying cancer cell surface marker in colorectal cancers. Int J Oncol 42(1): 161-167, 2013

40
Tanaka K., Miyata H., Yamasaki M., Sugimura K., Takahashi T., Kurokawa Y., Nakajima K., Takiguchi S., Mori M., Doki Y. Circulating miR-200c Levels Significantly Predict Response to Chemotherapy and Prognosis of Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Cancer. Ann Surg Oncol Suppl 3 607-615, 2013

41
Tanaka K., Miyashiro I., Yano M., Kishi K., Motoori M., Shingai T., Noura S., Ohue M., Ohigashi H., Ishikawa O. Visceral fat changes after distal gastrectomy according to type of reconstruction procedure for gastric cancer. World J Surg Oncol (11) : 146, 2013

42
Hirota M., Nakajima K., Souma Y., Mikata S., Iwase K., Demura K., Takahashi T., Yamasaki M., Miyata H., Kurokawa., Takiguchi S., Mori M., Doki Y. Assistive esophagoscopy during laparoscopic surgery for intra-thoracic stomach. Esophagus 19(2):70-78, 2013

43
Ogino T., Nishimura J., Barman S., Kayama H., Uematsu S., Okuzaki D., Osawa H., Haraguchi N., Uemura M., Hata T., Takemasa I., Mizushima T., Yamamoto H., Takeda K., Doki Y., Mori M. Increased Th17-Inducing Activity of CD14(+) CD163(low) Myeloid Cells in Intestinal Lamina Propria of Patients With Crohn's Disease. Gastroenterology 145(6): 1380-1391, 2013

44
Yamada D., Kobayashi S., Wada H., Kawamoto K., Marubashi S., Eguchi H., Ishii H., Nagano H., Doki Y., Mori M. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 49(7):1725-1740, 2013

45
Iwagami Y., Eguchi H., Nagano H., Akita H., Hama N., Wada H., Kawamoto K., Kobayashi S., Tomokuni A., Tomimaru Y., Mori M., Doki Y. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer 109(2):502-511, 2013

46
Ohtsuka M., Yamamoto H., Masuzawa T., Takahashi H., Uemura M., Haraguchi N., Nishimura J., Hata T., Yamasaki M., Miyata H., Takemasa I., Mizushima T., Takiguchi S., Doki Y., Mori M. C4.4A expression is associated with a poor prognosis of esophageal squamous cell carcinoma. Ann Surg Oncol 20(8): 2699-2705, 2013

47
Ohtsuka M., Yamamoto H., Oshiro R., Takahashi H., Masuzawa T., Uemura M., Haraguchi N., Nishimura J., Hata T., Yamasaki M., Takemasa I., Miyata H., Mizushima T., Takiguchi S., Doki Y., Mori M. Concurrent expression of C4.4A and Tenascin-C in tumor cells relates to poor prognosis of esophageal squamous cell carcinoma. Int J Oncol 43(2): 439-446, 2013

48
Takahashi Y., Sawada G., Sato T., Kurashige J., Mima K., Matsumura T., Uchi R., Ueo H., Ishibashi M., Takano Y., Akiyoshi S., Eguchi H., Sudo T., Sugimachi K., Tanaka J., Kudo SE., Doki Y., Mori M., Mimori K. Microarray analysis reveals that high mobility group A1 is involved in colorectal cancer metastasis. Oncol Rep 30(3):1488-1496, 2013

49
Takahashi Y., Sawada G., Kurashige J., Uchi R., Matsumura T., Ueo H., Takano Y., Akiyoshi S., Eguchi H., Sudo T., Sugimachi K., Doki Y., Mori M., Mimori K. Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer. Br J Cancer 109(2):307-311, 2013

50
Takahashi Y., Sawada G., Kurashige J., Matsumura T., Uchi R., Ueo H., Ishibashi M., Takano Y., Akiyoshi S., Iwaya T., Eguchi H., Sudo T., Sugimachi K., Yamamoto H., Doki Y., Mori M., Mimori K. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res 33(5): 1927-1934, 2013

51
Nishikawa S., Konno M., Hamabe A., Hasegawa S., Ogawa H., Kano Y., Fukusumi T., Ohta K., Noguchi Y, Ozaki M., Kudo T., Sakai D., Haraguchi N., Satoh T.,Doki Y., Mori M. and Ishii H. Aldehyde dehydrogenasehigh gastric cancer stem cells are resistant to chemotherapy. International Journal of Oncology 42: 1437-1442, 2013

52
Nishikawa S., Konno M., Hamabe A., Hasegawa S., Ogawa H., Kano Y., Fukusumi T., Ohta K., Noguchi Y, Ozaki M., Kudo T., Sakai D., Haraguchi N., Satoh T.,Doki Y., Mori M. and Ishii H. Eradication of therapy-resistant cancer cells in gastrointestinal organs. MOLECULAR AND CLINICAL ONCOLOGY 1:15-17, 2013

53
Hiura Y., Takiguchi S, Yamamoto K, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M, Doki Y. Use of fibrin glue sealant with polyglycolic acid sheets to prevent pancreatic fistula formation after laparoscopic-assisted gastrectomy. Surg Today 43(5): 527-533, 2013

54
Machida T., Tanemura M., Ohmura Y., Tanida T., Wada H., Kobayashi S., Marubashi S., Eguchi H., Ito T., Nagano H., Mori M., Doki Y., Sawa Y. Significant improvement in islet yield and survival with modified ET-Kyoto solution: ET-Kyoto/Neutrophil elastase inhibitor. Cell Transplant 22(1): 159-173, 2013

55
Marubashi S., Kobayashi S., Wada H., Kawamoto K., Eguchi H., Doki Y., Mori M., Nagano H. Hepatic artery reconstruction in living donor liver transplantation: risk factor analysis of complication and a role of MDCT scan for detecting anastomotic stricture. World J Surg 37(11): 2671-2677, 2013

56
Suzuki R., Yamamoto H., Ngan CY., Ohtsuka M., Kitani K., Uemura M., Nishimura J., Takemasa I., Mizushima T., Sekimoto M., Minamoto T., Doki Y., Mori M. Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. Int J Oncol 43(5): 1447-1455, 2013

57
Takahashi H., Yamasaki M., Hirota M., Miyazaki Y., Moon JH., Souma Y., Mori M., Doki Y., Nakajima K. Automatic smoke evacuation in laparoscopic surgery: a simplified method for objective evaluation. Surg Endosc 27(8): 2980-2987, 2013

58
Takiuchi D., Eguchi H., Nagano H., Iwagami Y., Tomimaru Y., Wada H., Kawamoto K., Kobayashi S., Marubashi S., Tanemura M., Mori M., Doki Y. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 13(5):517-523, 2013